| Budget Amount *help |
¥110,500,000 (Direct Cost: ¥85,000,000、Indirect Cost: ¥25,500,000)
Fiscal Year 2022: ¥23,790,000 (Direct Cost: ¥18,300,000、Indirect Cost: ¥5,490,000)
Fiscal Year 2021: ¥23,790,000 (Direct Cost: ¥18,300,000、Indirect Cost: ¥5,490,000)
Fiscal Year 2020: ¥23,790,000 (Direct Cost: ¥18,300,000、Indirect Cost: ¥5,490,000)
Fiscal Year 2019: ¥23,790,000 (Direct Cost: ¥18,300,000、Indirect Cost: ¥5,490,000)
Fiscal Year 2018: ¥15,340,000 (Direct Cost: ¥11,800,000、Indirect Cost: ¥3,540,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to develop an in vitro system to produce oocytes that achieves high integrity from primordial germ cells. Excessive activation of estrogen signaling in vitro-derived ovaries led to premature expression of AMH, resulting in abnormal follicle formation. On the other hand, the addition of AFP, which is secreted from fetal liver, to the culture medium suppressed estrogen signaling and resulted in normal follicle formation. Furthermore, lowering the concentration of oxygen from 20 to 7% during follicle culture improved abnormal lipid metabolism, restored mitochondrial activity, and improved post-fertilization development in the oocytes. The combination of this in vitro system and the exogenous transfection method via virus vector was shown to rescue oogenesis in congenitally infertile female mice. Thus, mouse oocytes that achieves high integrity were successfully produced in vitro.
|
